ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, a new class of STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitors was introduced for CML-therapy that have different binding capacity and mode of action compared to the ATP-competitive second and third generation TKIs [1].